Exhibits and Industry Support

Be seen at The Liver Meeting! The world’s premier meeting on liver disease provides ample avenues for industry supporters to raise awareness of their products and services.

TLM 2021 Has Started! Join the Conference
Man sitting in front of laptop Man sitting in front of laptop

Exhibits

AASLD has cancelled the in-person component to The Liver Meeting out of concerns around the COVID-19 virus and its variants. However, partners still have the opportunity to exhibit virtually along with a myriad of additional digital sponsorship options. and in-person! The TLMdX platform provides supporters with the flexibility to right-size their presence based on their desired visibility. See all our exhibiting options in the digital prospectus.

Product Theaters

Present new research, demonstrate key findings, and discuss the latest treatments with an audience of medical professionals at The Liver Meeting®. Product Theaters are 30- or 60-minute presentations hosted in the TLMdX platform. These sessions do not offer CME credit; rather, they give exhibitors the freedom to create a presentation centered on their company’s products and/or services.

NASH with Fibrosis: Updates from the MAESTRO Phase 3 Clinical Program

1:00 PM – 2:00 PM, Friday , November 12
Supported by: Madrigal Pharmaceuticals
Speakers: Manal Abdelmalek, MD and Mazen Noureddin, MD

Resmetirom is an investigational drug being evaluated for the treatment of NASH with fibrosis in two Phase 3 studies: MAESTRO-NASH (NCT03900429) and MAESTRO-NAFLD-1 (NCT04197479). Manal Abdelmalek, MD and Mazen Noureddin, MD will discuss disease state information and data from the open label arm of MAESTRO-NAFLD-1 and MAESTRO-NASH, respectively.

Understanding the symptoms of primary biliary cholangitis (PBC) – are we even scratching the surface?

2:00 PM – 2:30 PM, Friday , November 12
Supported by: GlaxoSmithKline
Speakers: Professors Cynthia Levy, David Jones, & Marlyn Mayo

Primary biliary cholangitis (PBC) is a rare, chronic, progressive cholestatic liver disease characterized by gradual destruction of the intrahepatic bile ducts. PBC is approximately nine times more common in women than in men and predominantly occurs in middle-age. Fatigue and pruritus are two major symptoms of PBC that have profound effects on patients and are often under-recognized by physicians. Discussing these symptoms with patients and utilizing simple tools in clinical practice to measure severity of fatigue and itch is important for an objective assessment of the impact on patient health and quality of life. Professors Cynthia Levy (University of Miami Miller School of Medicine), David Jones (Newcastle University and Newcastle Hospitals NHS Foundation Trust), and Marlyn Mayo (University of Texas Southwestern Medical Center) will focus on these important symptoms that patients with PBC experience and will discuss the need for a patient-centric approach to the management of fatigue and itch.

The ELF Test as a universally available prognostic tool for enhancing NASH patient care: 
Perspectives from hepatology and endocrinology

2:00 PM – 3:00 PM, Friday , November 12
Supported by: Siemens Healthineers
Siemens Moderator: H. Roma Levy, MS
Presenters: Scott Issacs, MD and Mazen Nouredidin, MD, MHSc

The Enhanced Liver Fibrosis (ELF™) Test​ is the first blood test granted De Novo marketing authorization by FDA for prognosis in advanced fibrosis due to NASH​. Attend this program to hear the clinical perspectives from two clinical thought leaders on how they see ELF positively impacting care for patients with advanced liver fibrosis.

Challenges in chronic hepatitis B clinical care: when to treat, when to stop treatment?

11:30 AM – 12:30 PM, Saturday, November 13
Supported by: GlaxoSmithKline
Speakers: Mindie Nguyen MD, FAASLD, Nezam H. Afdha MD, DSC, and Teresa Wright MD, AGAF, FAASLD 

In this product theater we will: 

  • Review the global burden of HBV
  • Discuss three challenging case studies in patients with chronic HBV infection
  • Immune tolerant HBeAg+ patient: to treat or not to treat?
  • Managing patients in the ‘grey zone’
  • HCC surveillance in CHB infection
  • Encourage audience participation in these challenging case presentations which aim to provide solutions for patients

Clinical Management of Patients with Hepatocellular Carcinoma

11:30 AM – 12:30 PM, Saturday, November 13
Supported by: Exelixis
Speakers: Sammy Saab, MD, MPH

This session provides an overview of the efficacy and safety of a tyrosine kinase inhibitor currently approved for use in patients with HCC. The discussion will also briefly cover topics such as HCC epidemiology, staging, guidelines, and treatment considerations.

Hepatitis D Virus Infection: Epidemiology, Pathophysiology, and Clinical Management

2:30 PM – 3:30 PM, Saturday, November 13
Supported by: Gilead Sciences, Inc.
Speakers: Douglas Dietrich, MD

This informative presentation provides clinicians with an in-depth review of hepatitis delta virus (HDV), the most severe form of chronic viral hepatitis. Topics covered include its global prevalence, relationship with hepatitis B virus, progression to advanced liver disease, and who to screen for HDV.

Bylvay™: the First and Only Drug Therapy for the Treatment of Pruritus in Patients with Progressive Familial Intrahepatic Cholestasis (PFIC)

3:00 PM – 3:30 PM, Saturday, November 13
Supported by: Albireo Pharmaceuticals
Speakers: Ryan Fischer, MD

Dr. Ryan Fischer will be discussing a treatment option available for patients living with Progressive Familial Intrahepatic Cholestasis (PFIC).

Liver Session: Biomarkers in Liver Transplant: Immune Privilege Does Not Justify Immune Ignorance

11:30 AM – 12:30 PM, Sunday, November 14
Supported by: Eurofins Transplant Diagnostics
Speakers: Sandy Feng, MD PhD, Josh Levitsky, MD, and James Trotter, MD

Key Take-Aways: 

  • Overview of clinical data and current practice challenges with immunosuppression minimization strategies in liver transplant recipients. 
  • Review of biomarkers of graft injury and rejection in monitoring the liver allograft 
  • Examine the state of precision medicine in liver transplantation and the potential for biomarkers to fill the unmet need

Satellite Symposia

AASLD offers commercial supporters of The Liver Meeting the opportunity to organize a limited number of independent educational symposia to be presented virtually for registered participants. Satellite symposia must be sponsored/organized by an ACCME accredited organization and offer CME credits. These symposia will take place at designated times following scheduled educational events and are designed to meet the continuing medical education needs of the hepatology community.

Current Landscape in the Systemic Treatment of Hepatobiliary Cancers: From Neoadjuvant Strategies to Advanced Disease

8:00 AM – 10:00 AM, Saturday, November 13
Supported by: Genentech, a member of the Roche Group
Organized by: Clinical Care Options, LLC
CME provided by: Clinical Care Options, LLC

On completion of this activity, participants should be able to:

  • Evaluate clinical data on the use of systemic treatment approaches for patients with early or intermediate-stage HCC
  • Plan optimal, individualized therapy approaches using immune checkpoint inhibitor–based regimens for patients with advanced or metastatic HCC, as clinically appropriate
  • Test tumors for biomarkers that can identify patients with hepatobiliary cancers suitable for targeted therapy
  • Select patients with hepatobiliary cancers most likely to benefit from immune checkpoint inhibitor–based combination therapy based on tumor characteristics, previous treatment, and patient characteristics and preferences
  • Develop strategies to identify and mitigate unique adverse events associated with immune checkpoint inhibitors and targeted therapies in patients with HCC or BTC

For more information, contact CCO Meetings Department at meetings@clinicaloptions.com or click here to register.  

Updates and Insights on HRS for the Liver Specialist

8:00 AM – 10:00 AM, Saturday, November 13
Supported by: Mallinckrodt
Organized by: Medscape Education
CME provided by: Medscape Education

On completion of this activity, participants should be able to:

  • Increased knowledge regarding the:
    • Clinical trial data for emerging treatments for HRS and acute kidney injury (AKI)
    • Gaps in current recognition and management of HRS-AKI
    • Current trends in HRS recognition, diagnosis, and management
  • Greater competence related to early recognition and management of HRS

Applying NASH: Tools for Earlier Diagnosis and Promising Emerging Therapies

7:00 PM – 9:00 PM, Saturday, November 13
Supported by: Perspectum Ltd. and Terns Pharmaceuticals
Organized by: Projects In Knowledge, Inc.
CME provided by: Projects In Knowledge, Inc.

On completion of this activity, participants should be able to:

  • Incorporate comprehensive noninvasive methodologies into the practice setting to better diagnose and grade NASH, and assess patients on treatment to optimize outcomes.
  • Assess the efficacy, safety, and mechanisms of action of investigational NASH therapies to better inform potential treatment strategies when approved by the FDA.
  • Consider combination therapies, when FDA approved, for patients with NASH based on their complementary mechanisms of action in blocking multiple pathogenic pathways.

For more information, contact Lori Marini at 973.890.8988 ext.104 or https://nash.atpointofcare.com.

Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance on Integrating Novel Locoregional, Multimodal and Systemic Strategies

8:00 AM – 10:00 AM, Sunday, November 14
Supported by: AstraZeneca, AVEO Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Inc., Exelixis, Inc., Genentech, and Novocure
Organized by: PVI, PeerView Institute for Medical Education
CME provided by: Medical Learning Institute, Inc.

Upon completion of this CE activity, participants should be better able to:

  • Assess the latest efficacy and safety evidence on available and emerging systemic treatments, including multikinase inhibitors, anti-angiogenic agents, and immune checkpoint inhibitors (as monotherapy or within a combination strategy) for patients with advanced HCC
  • Review ongoing clinical trials and recent data for innovative strategies, including tumor treating fields, Y-90 glass and resin microspheres, and locoregional combinations with systemic therapies, across the HCC disease spectrum
  • Develop personalized treatment plans for patients with early- to advanced-stage HCC, inclusive of clinical trial enrollment when appropriate, that are based on the latest clinical evidence, practice guidelines, treatment history, and other patient- and disease-specific factors
  • Apply best practices for collaboration and coordination of care among the multidisciplinary HCC care team to optimize patient assessment and treatment and minimize treatment-related toxicities

 For more information, contact PVI, PeerView Institute for Medical Education at 1.877.833.6141 or www.PeerView.com/HCC-Live21-Virtual.

Getting Closer to Targeted Therapies for NASH: Are You Ready?

7:00 PM – 8:30 PM, Sunday, November 14
Supported by: Novo Nordisk
Organized by: CME Outfitters, LLC
CME provided by: CME Outfitters, LLC

On completion of this activity, participants should be able to:

  • Select appropriate noninvasive diagnostic tests to stratify risk in patients with NAFLD/NASH.
  • Incorporate currently recommended therapies and interventions for preventing serious or fatal complications of disease/comorbidities into the plan of care for patients with NAFLD/NASH.
  • Identify the molecular basis of pharmacologic agents in late-stage clinical trials for the treatment of NASH. 

For more information please visit http://www.cmeoutfitters.com/NASH2021